封面
市場調查報告書
商品編碼
1881658

焦慮症和憂鬱症治療市場-全球產業規模、佔有率、趨勢、機會和預測,按產品、適應症、地區和競爭格局分類,2020-2030年預測

Anxiety Disorders and Depression Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Indication, By Region, By Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球焦慮症和憂鬱症治療市場規模為112.7億美元,預計到2030年將以5.93%的複合年成長率成長至159.2億美元。全球焦慮症和憂鬱症治療市場涵蓋一系列藥物干預措施,包括抗憂鬱藥物、抗焦慮藥物和情緒穩定劑,以及各種心理治療方法和神經刺激技術,旨在緩解症狀並改善患有這些普遍存在的精神健康問題的患者的預後。

市場概覽
預測期 2026-2030
2024年市場規模 112.7億美元
2030年市場規模 159.2億美元
2025-2030年複合年成長率 5.93%
成長最快的細分市場 抗憂鬱藥
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章:產品概述

第2章:研究方法

第3章:執行概要

第4章:顧客之聲

第5章:全球焦慮症與憂鬱症治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品(抗憂鬱藥物、療法和器械,其他)
    • 依適應症(強迫症、重度憂鬱症、恐懼症、其他)
    • 按地區
    • 按公司(2024 年)
  • 市場地圖

第6章:北美焦慮症與憂鬱症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲:國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章:歐洲焦慮症與憂鬱症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲:國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章:亞太地區焦慮症與憂鬱症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章:中東和非洲焦慮症和憂鬱症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲:國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章:南美洲焦慮症與憂鬱症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲:國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章:市場動態

  • 促進要素
  • 挑戰

第12章:市場趨勢與發展

  • 併購(如有)
  • 產品發布(如有)
  • 最新進展

第13章:全球焦慮症與憂鬱症治療市場:SWOT分析

第14章:波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章:競爭格局

  • Abbvie Inc.
  • Bristol-Myers Squibb Company
  • Eli Lily & Co
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc
  • Pfizer Inc
  • Sanofi
  • Axsome Therapeutics Inc

第16章:策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 22193

The Global Anxiety Disorders and Depression Treatment Market, valued at USD 11.27 Billion in 2024, is projected to experience a CAGR of 5.93% to reach USD 15.92 Billion by 2030. The Global Anxiety Disorders and Depression Treatment Market encompasses a range of pharmacological interventions, including antidepressants, anxiolytics, and mood stabilizers, alongside various psychotherapeutic modalities and neurostimulation techniques designed to alleviate symptoms and improve outcomes for individuals suffering from these pervasive mental health conditions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 11.27 Billion
Market Size 2030USD 15.92 Billion
CAGR 2025-20305.93%
Fastest Growing SegmentAntidepressant Drugs
Largest MarketNorth America

Key Market Drivers

The Global Anxiety Disorders and Depression Treatment Market is significantly influenced by the escalating worldwide incidence of mental health conditions and ongoing innovations in therapeutic strategies. The rising global prevalence of anxiety and depression disorders directly expands the addressable patient population requiring interventions, thereby acting as a fundamental growth catalyst for the market. This demographic shift necessitates broader access to diagnostic tools and diverse treatment options.

Key Market Challenges

The substantial economic burden linked to developing and delivering novel therapeutic solutions directly impedes the growth of the Global Anxiety Disorders and Depression Treatment Market. The extensive research and development phases for new antidepressants, anxiolytics, and advanced neurostimulation techniques necessitate considerable financial investment. These high costs ultimately translate into elevated pricing for new treatments, making them less accessible, particularly in regions with limited healthcare budgets and less developed infrastructure.

Key Market Trends

The expansion of digital therapeutics and telehealth solutions significantly influences the anxiety disorders and depression treatment market by enhancing accessibility and scalability of care. These platforms leverage technology to deliver evidence-based interventions remotely, reaching a broader patient population, particularly in underserved areas. According to GSMA's Mobile Economy 2024 report, approximately 5.6 billion people worldwide were mobile service subscribers in 2023, providing a vast infrastructure for these digital health services.

Key Market Players

  • Abbvie Inc.
  • Bristol-Myers Squibb Company
  • Eli Lily & Co
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc
  • Pfizer Inc
  • Sanofi
  • Axsome Therapeutics Inc

Report Scope:

In this report, the Global Anxiety Disorders and Depression Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anxiety Disorders and Depression Treatment Market, By Product:

  • Antidepressant Drugs
  • Therapy and Devices
  • Others

Anxiety Disorders and Depression Treatment Market, By Indication:

  • Obsessive-Compulsive Disorder
  • Major Depressive Disorder
  • Phobia
  • Others

Anxiety Disorders and Depression Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anxiety Disorders and Depression Treatment Market.

Available Customizations:

Global Anxiety Disorders and Depression Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anxiety Disorders and Depression Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Antidepressant Drugs, Therapy and Devices, Others)
    • 5.2.2. By Indication (Obsessive-Compulsive Disorder, Major Depressive Disorder, Phobia, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Anxiety Disorders and Depression Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Indication
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Anxiety Disorders and Depression Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Indication
    • 6.3.2. Canada Anxiety Disorders and Depression Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Indication
    • 6.3.3. Mexico Anxiety Disorders and Depression Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Indication

7. Europe Anxiety Disorders and Depression Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Indication
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Anxiety Disorders and Depression Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Indication
    • 7.3.2. France Anxiety Disorders and Depression Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Indication
    • 7.3.3. United Kingdom Anxiety Disorders and Depression Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Indication
    • 7.3.4. Italy Anxiety Disorders and Depression Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Indication
    • 7.3.5. Spain Anxiety Disorders and Depression Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Indication

8. Asia Pacific Anxiety Disorders and Depression Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Indication
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Anxiety Disorders and Depression Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Indication
    • 8.3.2. India Anxiety Disorders and Depression Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Indication
    • 8.3.3. Japan Anxiety Disorders and Depression Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Indication
    • 8.3.4. South Korea Anxiety Disorders and Depression Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Indication
    • 8.3.5. Australia Anxiety Disorders and Depression Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Indication

9. Middle East & Africa Anxiety Disorders and Depression Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Indication
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Anxiety Disorders and Depression Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Indication
    • 9.3.2. UAE Anxiety Disorders and Depression Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Indication
    • 9.3.3. South Africa Anxiety Disorders and Depression Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Indication

10. South America Anxiety Disorders and Depression Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Indication
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Anxiety Disorders and Depression Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Indication
    • 10.3.2. Colombia Anxiety Disorders and Depression Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Indication
    • 10.3.3. Argentina Anxiety Disorders and Depression Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Anxiety Disorders and Depression Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbvie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bristol-Myers Squibb Company
  • 15.3. Eli Lily & Co
  • 15.4. GlaxoSmithKline Plc
  • 15.5. H. Lundbeck A/S
  • 15.6. Johnson & Johnson Services, Inc.
  • 15.7. Merck & Co. Inc
  • 15.8. Pfizer Inc
  • 15.9. Sanofi
  • 15.10. Axsome Therapeutics Inc

16. Strategic Recommendations

17. About Us & Disclaimer